Aveo drops on delay for Phase III tvozanib readout

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) fell $0.69 (24%) to $2.16 on July 17 after delaying for at least the second time an expected

Read the full 222 word article

User Sign In